Acousia Therapeutics GmbH
acousia.com
Actively hiring
Biotechnology
Biotechnology
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Overview
Acousia Therapeutics GmbH is a privately held biotech company based in Tübingen, Germany, dedicated to identify small molecules for an innovative treatment of hearing loss.
News
Promising First-in-Patient Results for ACOU085 (INN: Bimokalner) in Cisplatin-Induced Ototoxicity
/! elementor - v3.5.5 - 03-02-2022 / .elementor-widget-text-editor.elementor-drop-cap-view-stacked .elementor-drop-cap{background-color:#818a91;color:#fff}.elementor-widget-text-editor.elementor-drop-cap-view-framed .elementor-drop-cap{color:#818a91;borde
Read more
Report
Acousia Announces Completion of Patient Enrollment in Phase 2 PROHEAR Study Evaluating ACOU085 (INN: Bimokalner) for the Prevention of Cisplatin-Induced Ototoxicity
Acousia Therapeutics GmbH, a clinical-stage biotechnology company developing treatments for acute and chronic inner ear hearing loss, announced the completion of patient enrollment in its Phase 2 PROHEAR clinical study. ACOU085 (INN: Bimokalner) is a prop
Read more
Report
PROHEAR Study highlighted as 'Study of the Month' by German Society of Urology
The German Society of Urology (Deutsche Gesellschaft für Urology, DGU) has highlighted Acousia's PROHEAR Study as their Study of the Month, acknowledging the urgent need for effective prevention of cisplatin-induced hearing loss in testicular cancer treat
Read more
Report
Acousia Therapeutics Reaches 50% Patient Enrollment Milestone in Phase 2 PROHEAR Study
Acousia Therapeutics GmbH announced that it has successfully enrolled 50% of patients in its ongoing Phase 2 clinical trial, the PROHEAR Study, evaluating ACOU085 (INN: bimokalner) for the prevention of cisplatin-induced hearing loss in patients with test
Read more
Report
Acousia Therapeutics Reaches 50% Patient Enrollment Milestone in Phase 2 PROHEAR Study
Acousia Therapeutics GmbH announced that it has successfully enrolled 50% of patients in its ongoing Phase 2 clinical trial, the PROHEAR Study, evaluating ACOU085 (INN: bimokalner) for the prevention of cisplatin-induced hearing loss in patients with test
Read more
Report
Acousia Therapeutics to present its clinical Phase 2 PROHEAR study on hearing loss treatment candidate ACOU085 at upcoming conferences
The PROHEAR study is a placebo-controlled Phase 2a study with split-body design investigating the otoprotective efficacy of ACOU085 in patients with testicular cancer undergoing high-dose, cisplatin-based chemotherapy regimens (cis-Pt 300 mg/m2). Formally
Read more
Report
Acousia Therapeutics to present its clinical Phase 2 PROHEAR study on hearing loss treatment candidate ACOU085 at upcoming conferences
Read more
Report
Hearing loss company Acousia announces first patient enrolled in its Phase 2 PROHEAR-Study
Acousia Therapeutics GmbH, a Tübingen-based clinical stage biotech company focused on the enhancement and preservation of natural hearing, just announced the randomization of the first patient for the PROHEAR-Study. The PROHEAR-Study is a placebo-controll
Read more
Report
Acousia Therapeutics attracts new investor on its path to make hearing loss a treatable disease
/! elementor - v3.5.5 - 03-02-2022 / .elementor-heading-title{padding:0;margin:0;line-height:1}.elementor-widget-heading .elementor-heading-titleclass=elementor-size-a{color:inherit;font-size:inherit;line-height:inherit}.elementor-widget-heading .elemento
Read more
Report
Hearing Loss Company Acousia Therapeutics Green Lighted for Game-Changing Phase 2 Trial
/PRNewswire/ -- Acousia Therapeutics, a pioneer clinical-stage biotech company focused on the development of novel drug therapies for the prevention and...
Read more
Report
Show more news